{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:57:37Z","timestamp":1787317057316,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T00:00:00Z","timestamp":1216339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetic Medicine"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2003<\/jats:bold>\n                    The UK Prospective Diabetes Study (UKPDS) was a randomised controlled clinical study which looked at the effect of improved blood glucose and blood pressure control on macro\u2010 and microvascular complications in Type 2 diabetes. Retinopathy was the commonest microvascular outcome and this paper looks at this complication.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2003<\/jats:bold>\n                    Newly diagnosed diabetic patients were randomised to intensive or conventional glycaemic control and a subset of hypertensive patients to tight or less tight blood pressure control. Patients were seen every 3\u00a0months in study clinics and retinopathy was assessed by adjudicated grading of triennial colour retinal photographs. Photocoagulation treatment, vitreous haemorrhage and cataract extraction were predefined UKPDS endpoints. Observational analyses of the data were used to examine the relationship of updated mean glycated haemoglobin (HbA\n                    <jats:sub>1c<\/jats:sub>\n                    ) and mean blood pressure levels to retinopathy outcomes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2003<\/jats:bold>\n                    The UKPDS showed that both improved glucose control and improved blood pressure control reduced the risk of retinopathy, with a linear relationship between the log hazard ratio for retinopathy and both updated mean HbA\n                    <jats:sub>1c<\/jats:sub>\n                    and updated mean blood pressure. A 1% decrement in HbA\n                    <jats:sub>1c<\/jats:sub>\n                    equated to a 31% reduction in retinopathy and a 10\u00a0mmHg decrement in systolic blood pressure equated to an 11% reduction in photocoagulation or vitreous haemorrhage. Evidence of retinopathy at diagnosis, including the presence of microaneurysms only, increased significantly the risk of progression to photocoagulation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2003<\/jats:bold>\n                    The UKPDS stands out as a landmark study in Type 2 diabetes, emphasising the crucial importance of controlling both blood glucose and blood pressure in order to minimise the risk of developing sight\u2010threatening retinopathy.\n                  <\/jats:p>","DOI":"10.1111\/j.1464-5491.2008.02505.x","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T06:34:19Z","timestamp":1216362859000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Microvascular disease: what does the UKPDS tell us about diabetic retinopathy?"],"prefix":"10.1111","volume":"25","author":[{"given":"E. M.","family":"Kohner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,18]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Symposium on the Treatment of Diabetic Retinopathy","author":"Goldberg MF","year":"1969"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.25.12.1129"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.28.1.41"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197608192950804"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.2.4.329"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38014-2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00458.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051278"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.11.1631"},{"issue":"2","key":"e_1_2_6_11_2","first-page":"A42","article-title":"Risk factors for presence of hard exudates at diagnosis of Type 2 diabetes and after 6\u00a0years. Abstract no. 116","volume":"46","author":"Stratton IM","year":"2003","journal-title":"Presented at the International Diabetes Federation (IDF) meeting in Paris, France"},{"issue":"1","key":"e_1_2_6_12_2","first-page":"90","article-title":"Visual loss related to the position of hard exudates in diabetic maculopathy in Type 2 diabetes in the UKPDS","volume":"24","author":"Stratton IM","year":"2007","journal-title":"Presented at the Diabetes UK Meeting"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS\u00a033)","volume":"352","author":"UK Prospective Study Group","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051594"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-8727(02)00161-7"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.412"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0297-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9016"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2174\/157339907779802139"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.7.2188"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.032"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2005.003"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100140281004"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.08.023"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-5491.2008.02505.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-5491.2008.02505.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T22:14:06Z","timestamp":1694643246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-5491.2008.02505.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,18]]},"references-count":24,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1464-5491.2008.02505.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02505.x","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,18]]},"assertion":[{"value":"2008-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}